All News Items
Giant with a Ceramic Heart
04.07.2024 / A new NMR spectrometer has been in operation at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) since the end of May. What makes it special is that it is based on a new type of ceramic high-temperature superconductor. Peter Schmieder, head of the NMR technology platform at the FMP, explains the technology behind it and the capabilities of the new device. … more
Pentixapharm Acquires Target Discovery Business of Glycotope
03.07.2024 / Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH. … more
Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler
01.07.2024 / Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a broad range of malignancies, announced today that the General Shareholder Meeting of Pentixapharm resolved the appointment of the distinguished endocrinologist Prof. Dr. med. Marcus Quinkler to the Company's Supervisory Board. The assignment will become effective with the registration of the split-off of Pentixapharm AG from Eckert & Ziegler SE in the commercial register. … more
Multiple myeloma: Early detection of aggressive tumors
28.06.2024 / Berlin researchers and their partners describe how aggressive variants of multiple myeloma can be detected early. Their comprehensive study in “Nature Cancer” shows how changes in genetic material affect the protein profile of the tumor cells, and thus the mechanisms involved in the disease. … more
Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
27.06.2024 / The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year. … more
3D maps of diseased tissues at subcellular precision
26.06.2024 / An open-source platform developed by researchers in Nikolaus Rajewsky’s lab at the Max Delbrück Center creates molecular maps from patient tissue samples with subcellular precision, enabling detailed study and potentially enhancing routine clinical pathology. The study was published in “Cell.” … more
Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
25.06.2024 / Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registration study with its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism (PA). PA is an adrenal gland disorder also known as Conn’s syndrome and the most frequent cause of secondary hypertension (high blood pressure). … more
Novel Cancer Therapeutic from FMP Research Enters Clinical Phase
21.06.2024 / Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa trial in tumour patients. Thanks to an innovative linker chemistry known as P5 technology, the active substance is delivered safely to its target and can also develop its effect over a long period of time. The beginning of a clinical trial just a few years after the discovery of the P5 technology is a major achievement that demonstrates the potential for applied research in an academic research institute. … more
Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
20.06.2024 / Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated yesterday with an official ceremony featuring Czech Prime Minister Petr Fiala, marks the culmination of a longstanding partnership between Eckert & Ziegler and UJF. The facility is now close to operational readiness, and after additional testing, commercial production is slated to commence at the beginning of Q3/2024. … more
Talk im Cube: Building the bridge from preclinical to clinical studies
13.06.2024 / Join us for the next edition of Talk im Cube … more
Eckert & Ziegler receives “Best Managed Companies Award”
24.05.2024 / Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstandingly managed medium-sized companies. … more
€700,000 boost for preeclampsia research
23.05.2024 / Preeclampsia is one of the most common pregnancy-related complications. Florian Herse of the Max Delbrück Center and Martin Gauster of the Medical University of Graz are studying the role that Hofbauer cells play in the disorder. They have been awarded a D-A-CH grant totaling €700,000 for their research. … more
Captain T Cell secures seed financing round
22.05.2024 / Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic. … more
Berlin-Buch goes BIO International Convention
21.05.2024 / The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Campus Berlin-Buch GmbH is attending this year's event in San Diego from June 3-6. … more
Talk im Cube: Sustainable Practices in Life Sciences - A Panel Discussion (in English)
16.05.2024 / Don't miss this opportunity to engage with experts as we chart a path towards a more sustainable future. … more
EU-OPENSCREEN ERIC Launches New EU-Funded Project IMPULSE
29.04.2024 / EU-OPENSCREEN ERIC proudly announces the launch of its latest EU-funded Horizon Europe project, IMPULSE, after a two-day kick-off event held earlier this month. … more
From cell biology to CRISPR/Cas – new knowledge for schools
15.04.2024 / The Life Science Learning Lab at the Berlin-Buch research campus offers both school students and teachers the opportunity to immerse themselves in science. This year, the facility celebrates its 25th anniversary … more
ERC grants Berlin scientists €2.5 million each
11.04.2024 / Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that underlie temperature perception. … more
The Protein Expert
09.04.2024 / Prof. Dr. Fan Liu from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has recently received several awards for her contributions to the field of cross-linking mass spectrometry. The scientist is dedicated to better understanding the interactions between proteins at the cellular level. Additionally, she is developing methods and standards to refine this complex and indispensable technology for many research questions, making it more broadly applicable. … more
Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
22.03.2024 / Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26. … more
Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
21.03.2024 / Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of prostate cancer as well as eye and brain tumors, obtained the MDR certificate for its proprietary prostate seeds from DEKRA Certification B.V. as one of the first companies in its market. This important milestone guarantees a high level of patient safety and the long-term availability of the seeds within the EU. … more
Eckert & Ziegler Completes Change of Legal Form to SE
19.03.2024 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Societas Europaea (SE) with entry in the company's commercial register and will in future operate as Eckert & Ziegler SE. … more
A new channel for touch
01.03.2024 / Touch is a fundamental, yet scarcely understood, sense. Now, the team led by Gary Lewin at the Max Delbrück Center has discovered a second ion channel associated with touch perception. Elkin1 could be a target for pain therapy, the team writes in “Science”. … more
Eckert & Ziegler Extends Ga-68 Activities in Japan
28.02.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan). For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm® as the single source for Ga-68. … more
FyoniBio collaborates with BioLamina and Alder Therapeutics
08.02.2024 / FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for its expertise in extracellular laminin-based cell biology and development of laminins as tools for cell culture, and Alder Therapeutics, a virtual preclinical allogeneic stem cell therapy development company. The consortium will advance the development of laminins for clinical applications. … more
Talk im Cube: Female Entrepreneurship - A Panel Discussion (in English)
08.02.2024 / Second edition in March 2024 … more
Pain and touch sensations require Schwann cells
07.02.2024 / Special receptor cells under the skin enable us to feel pain and touch. But Schwann cells also play a key role in detecting such stimuli, researchers at the Max Delbrück Center report in “Nature Communications.” This discovery opens new avenues for pain therapy. … more
Gene editing precisely repairs immune cells
05.02.2024 / Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in “Science Immunology.” … more
Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
31.01.2024 / Eckert & Ziegler's supply of Lu-177 and Ac-225 enables Nucleus Radiopharma entering a new era in cancer care … more
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
23.01.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler's high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals. … more
Third ERC Grant for Gaetano Gargiulo
18.01.2024 / Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant. … more
"More Entrepreneurial Thinking in Research"
12.01.2024 / Interview with Professor Maike Sander, Scientific Director of the Max Delbrück Center … more
Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
11.01.2024 / Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces it has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a Phase 1 trial of 123I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma. … more
Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
08.01.2024 / Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert & Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies using its proprietary AlphaDirectTM Lead-212 (Pb-212) isolation technology. … more
New agent regulates serotonin production
27.12.2023 / Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market. … more
A neuromuscular model for drug development
19.12.2023 / In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in “Nature Communications”, they say the new model promises to revolutionize high-throughput drug screening studies. … more
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
15.12.2023 / CELLphenomics’ PD3D® tumor model platform will expand Charles River’s portfolio of 3D in vitro testing services … more
Berlin Cures advances fight against Long COVID on a pan-European level
14.12.2023 / Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID. A total of 12 sites in Germany, Austria, Switzerland, Finland and Spain are working to advance clinical research into this escalating global health problem. Additional trial sites in Switzerland, Spain and Germany are expected to soon follow. First results of the Phase II trial are expected in 2024. In the event of positive results, Berlin Cures is aiming for a larger Phase III study, which is a prerequisite for the approval of BC 007. … more
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
11.12.2023 / Glycotope GmbH (Glycotope) has signed an agreement with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec. … more
What do scientists actually do in the lab?
30.11.2023 / Grizzly bears in hibernation or a pineapple in an MRI scanner – at the “Science Day” at the “Robert Havemann” high school in Berlin-Karow, researchers from the Max Delbrück Center presented students of grades 11 and 12 unusual facets of their research. … more
A new hub for cutting-edge cancer care
25.11.2023 / From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research. … more
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
23.11.2023 / Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University Hospital in Essen, Germany. … more
Personnel Changes in the Management of Eckert & Ziegler AG
22.11.2023 / Changes in the Executive Board and Supervisory Board … more
Heart repair via neuroimmune crosstalk
17.11.2023 / Unlike humans, zebrafish can completely regenerate their hearts after injury. They owe this ability to the interaction between their nervous and immune systems, as researchers led by Suphansa Sawamiphak from the Max Delbrück Center now report in the journal “Developmental Cell.” … more
Lisec-Artz Prize goes to Simon Haas
15.11.2023 / Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers. … more
Influential in their field
15.11.2023 / Sofia Forslund, Friedemann Paul, and Nikolaus Rajewsky are among the Highly Cited Researchers 2023. Each year the company Clarivate compiles a "Who's Who" list of highly influential researchers. … more
Eckert & Ziegler Establishess German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
14.11.2023 / Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). … more
Eckert & Ziegler Establishess German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
14.11.2023 / Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). … more
Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
14.11.2023 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month result was around € 2 million higher than the previous year's figure. In addition, there was an increase in expenses for future projects in the field of nuclear medicine diagnostics and therapy. … more
Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules
01.11.2023 / Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital. Seed financing will drive commercial growth for Cambrium’s first product, NovaColl™, and accelerate expansion into new industries … more
Events
all events
10.09.2024, 09:00-
13.09.2024, 18:00
From Target to Market - The GLA Biotech & Pharma Summer School
12.09.2024, 09:00-
13.09.2024, 17:00
realtime PCR und digital PCR Kurs
08.10.2024, 09:00-
17.10.2024, 18:00
GMP Biotech Summer School